150 related articles for article (PubMed ID: 28368903)
1. The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy.
Kaidar-Person O; Zagar TM; Deal A; Moschos SJ; Ewend MG; Sasaki-Adams D; Lee CB; Collichio FA; Fried D; Marks LB; Chera BS
Anticancer Drugs; 2017 Jul; 28(6):669-675. PubMed ID: 28368903
[TBL] [Abstract][Full Text] [Related]
2. Survival Benefit of Stereotactic Radiotherapy in the Complex Management of Metastatic Melanoma.
Kelemen G; Együd Z; Dobi Á; Varga L; Kószó R; Borzási E; Paczona V; Végváry Z; Borzák F; Fodor E; Ócsai H; Baltás E; Oláh J; Hideghéty K
Anticancer Res; 2024 Jan; 44(1):205-212. PubMed ID: 38159978
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the risk factors in the development of radionecrosis in patients with brain metastases undergoing stereotactic radiotherapy.
Doğan B; Demir H; Işık N; Gunalp G; Günbey HP; Yaprak G
Br J Radiol; 2024 May; 97(1157):1022-1028. PubMed ID: 38426391
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with radiation necrosis and intracranial control in patients treated with immune checkpoint inhibitors and stereotactic radiotherapy.
Hall J; Lui K; Tan X; Shumway J; Collichio F; Moschos S; Sengupta S; Chaudhary R; Quinsey C; Jaikumar S; Forbes J; Andaluz N; Zuccarello M; Struve T; Vatner R; Pater L; Breneman J; Weiner A; Wang K; Shen C
Radiother Oncol; 2023 Dec; 189():109920. PubMed ID: 37769968
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Immune Checkpoint Inhibition on the Risk of Radiation Necrosis Following Stereotactic Radiotherapy for Metastatic Brain Cancer.
Royal-Preyra B
Cureus; 2023 Dec; 15(12):e51381. PubMed ID: 38161546
[TBL] [Abstract][Full Text] [Related]
6. 'Immunotherapeutic Strategies for Intra-cranial Metastatic Melanoma - a Meta-analysis and Systematic Review'.
Tang HKC; Rao A; Peters C; Ambulkar T; Ho MF; Wang B; Patel P
J Cancer; 2024; 15(11):3495-3509. PubMed ID: 38817862
[TBL] [Abstract][Full Text] [Related]
7. Melanoma Brain Metastasis: Mechanisms, Models, and Medicine.
Kircher DA; Silvis MR; Cho JH; Holmen SL
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27598148
[TBL] [Abstract][Full Text] [Related]
8. Intracranial response after extracranial radiation in a patient with rapidly progressing metastatic melanoma.
Piercey O; Tomaszewski JM; Smith K
BMJ Case Rep; 2021 Jun; 14(6):. PubMed ID: 34088687
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy Combined with Radiation in Malignant Melanoma without BRAF Mutations Brain Metastases-Favorable Response after Immunotherapy Continued beyond Progression.
Rahnea-Nita RA; Rebegea LF; Toma RV; Mocanu H; Soare I; Mihailov R; Nechifor A; Guliciuc M; Constantin GB; Rahnea-Nita G
J Pers Med; 2024 Jan; 14(1):. PubMed ID: 38248787
[TBL] [Abstract][Full Text] [Related]
10. Can radiation restore immunotherapy response in metastatic melanoma refractory to checkpoint inhibitors: An institutional experience in salvaging immunotherapy resistant disease.
Alhumaid M; Dinakaran D; Smylie M; Walker J; Joseph K
Radiother Oncol; 2023 Aug; 185():109712. PubMed ID: 37178931
[TBL] [Abstract][Full Text] [Related]
11. Complications associated with immunotherapy for brain metastases.
Tran TT; Jilaveanu LB; Omuro A; Chiang VL; Huttner A; Kluger HM
Curr Opin Neurol; 2019 Dec; 32(6):907-916. PubMed ID: 31577604
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy: an emerging modality to checkmate brain metastasis.
Ahmad A; Khan P; Rehman AU; Batra SK; Nasser MW
Mol Cancer; 2023 Jul; 22(1):111. PubMed ID: 37454123
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy as a Turning Point in the Treatment of Melanoma Brain Metastases.
Fernandes GNC
Discoveries (Craiova); 2023; 11(2):e169. PubMed ID: 37583899
[TBL] [Abstract][Full Text] [Related]
14. Good Gone Bad: Complications of Chemotherapy, Immunotherapy, and Radiotherapy on the CNS.
Mallikarjun KS; Eldaya RW; Miller-Thomas MM; Orlowski HL; Parsons MS
Curr Probl Diagn Radiol; 2024; 53(1):133-149. PubMed ID: 37495483
[TBL] [Abstract][Full Text] [Related]
15. Editorial: Radiotherapy strategies for precise treatment on brain metastases.
Lehrer EJ; Breen WG; Sener U; Campian JL
Front Oncol; 2024; 14():1366261. PubMed ID: 38571498
[No Abstract] [Full Text] [Related]
16. Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation.
Martin AM; Cagney DN; Catalano PJ; Alexander BM; Redig AJ; Schoenfeld JD; Aizer AA
JAMA Oncol; 2018 Aug; 4(8):1123-1124. PubMed ID: 29327059
[TBL] [Abstract][Full Text] [Related]
17. Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Nardin C; Mateus C; Texier M; Lanoy E; Hibat-Allah S; Ammari S; Robert C; Dhermain F
Melanoma Res; 2018 Apr; 28(2):111-119. PubMed ID: 29356789
[TBL] [Abstract][Full Text] [Related]
18. Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment.
Anderson ES; Postow MA; Wolchok JD; Young RJ; Ballangrud Å; Chan TA; Yamada Y; Beal K
J Immunother Cancer; 2017 Oct; 5(1):76. PubMed ID: 29037215
[TBL] [Abstract][Full Text] [Related]
19. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.
Diao K; Bian SX; Routman DM; Yu C; Kim PE; Wagle NA; Wong MK; Zada G; Chang EL
J Neurosurg; 2018 Dec; 129(6):1397-1406. PubMed ID: 29303446
[TBL] [Abstract][Full Text] [Related]
20. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
